Paul J Clark

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. doi request reprint Genetic variation in IL28B: impact on drug development for chronic hepatitis C infection
    P J Clark
    Duke Clinical Research Institute and Division of Gastroenterology, Duke University Medical Center, Durham, North Carolina, USA
    Clin Pharmacol Ther 88:708-11. 2010
  2. doi request reprint IL28B genomic-based treatment paradigms for patients with chronic hepatitis C infection: the future of personalized HCV therapies
    Paul J Clark
    Duke Clinical Research Institute and Division of Gastroenterology, Duke University Medical Center, School of Medicine, Duke University, Durham, North Carolina 27715, USA
    Am J Gastroenterol 106:38-45. 2011
  3. pmc Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response
    Susanna Naggie
    Duke Clinical Research Institute, Durham, NC, USA
    Hepatology 56:444-54. 2012
  4. pmc The association of genetic variants with hepatic steatosis in patients with genotype 1 chronic hepatitis C infection
    Paul J Clark
    Duke Clinical Research Institute, Duke University, PO Box 17969, Durham, NC 27715, USA
    Dig Dis Sci 57:2213-21. 2012
  5. pmc Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C
    Hans L Tillmann
    Duke Clinical Research Institute and Division of Gastroenterology, Duke University Medical Center, Durham, NC 27705, USA
    J Hepatol 55:1195-200. 2011
  6. doi request reprint Hepatitis C virus selectively perturbs the distal cholesterol synthesis pathway in a genotype-specific manner
    Paul J Clark
    Duke Clinical Research Institute and Department of Gastroenterology, Duke University Medical Center, Durham, NC 27715, USA
    Hepatology 56:49-56. 2012
  7. pmc Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia in HIV/HCV-coinfected patients with all HCV genotypes
    Susanna Naggie
    Duke Clinical Research Institute, Durham, North Carolina, USA
    J Infect Dis 205:376-83. 2012
  8. pmc Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients
    Alexander J Thompson
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27701, USA
    J Hepatol 56:313-9. 2012
  9. doi request reprint Host genomics and HCV treatment response
    Paul J Clark
    Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
    J Gastroenterol Hepatol 27:212-22. 2012
  10. pmc Characterization of serum proteins associated with IL28B genotype among patients with chronic hepatitis C
    Derek D Cyr
    Institute for Genome Sciences and Policy, Duke University Medical Center, Durham, North Carolina, United States of America
    PLoS ONE 6:e21854. 2011

Collaborators

Detail Information

Publications13

  1. doi request reprint Genetic variation in IL28B: impact on drug development for chronic hepatitis C infection
    P J Clark
    Duke Clinical Research Institute and Division of Gastroenterology, Duke University Medical Center, Durham, North Carolina, USA
    Clin Pharmacol Ther 88:708-11. 2010
    ....
  2. doi request reprint IL28B genomic-based treatment paradigms for patients with chronic hepatitis C infection: the future of personalized HCV therapies
    Paul J Clark
    Duke Clinical Research Institute and Division of Gastroenterology, Duke University Medical Center, School of Medicine, Duke University, Durham, North Carolina 27715, USA
    Am J Gastroenterol 106:38-45. 2011
    ..Future studies will investigate the possibility of individualizing treatment duration and novel regimens according to IL28B type...
  3. pmc Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response
    Susanna Naggie
    Duke Clinical Research Institute, Durham, NC, USA
    Hepatology 56:444-54. 2012
    ..004). Induction of innate immunity genes was also lower in unfavorable genotypes. ISG expression at baseline and induction with IFN was independent of IL28B genotype...
  4. pmc The association of genetic variants with hepatic steatosis in patients with genotype 1 chronic hepatitis C infection
    Paul J Clark
    Duke Clinical Research Institute, Duke University, PO Box 17969, Durham, NC 27715, USA
    Dig Dis Sci 57:2213-21. 2012
    ..Single-nucleotide polymorphisms (SNPs) in the IL28B and PNPLA3 gene regions have been associated with hepatic steatosis in genotype 1 (G1) chronic HCV infection but their clinical impacts remain to be determined...
  5. pmc Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C
    Hans L Tillmann
    Duke Clinical Research Institute and Division of Gastroenterology, Duke University Medical Center, Durham, NC 27705, USA
    J Hepatol 55:1195-200. 2011
    ..Here we analyzed the association of steatosis with IL28B genotype in treatment naïve patients with CHC...
  6. doi request reprint Hepatitis C virus selectively perturbs the distal cholesterol synthesis pathway in a genotype-specific manner
    Paul J Clark
    Duke Clinical Research Institute and Department of Gastroenterology, Duke University Medical Center, Durham, NC 27715, USA
    Hepatology 56:49-56. 2012
    ..2 mg/dL; P(adj) = 0.0015], 7DHC [Δ0.0075 mg/dL; P(adj) = 0.0026], lathosterol [Δ0.0430 mg/dL P(adj) = 0.0405]). In contrast, lanosterol was unchanged after SVR (P = 0.9515)...
  7. pmc Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia in HIV/HCV-coinfected patients with all HCV genotypes
    Susanna Naggie
    Duke Clinical Research Institute, Durham, North Carolina, USA
    J Infect Dis 205:376-83. 2012
    ..We investigate these polymorphisms in a cohort of human immunodeficiency virus (HIV)/HCV-coinfected patients...
  8. pmc Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients
    Alexander J Thompson
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27701, USA
    J Hepatol 56:313-9. 2012
    ..We performed a genome wide association study on a well-characterized genotype 1 HCV cohort to identify genetic determinants of peginterferon-α (pegIFN)-related thrombocytopenia, neutropenia, and leukopenia...
  9. doi request reprint Host genomics and HCV treatment response
    Paul J Clark
    Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
    J Gastroenterol Hepatol 27:212-22. 2012
    ..Finally, pegylated-IFN and ribavirin is no longer the standard of care for the treatment of G1 HCV, and we conclude by considering the relevance of IL28B polymorphisms in the era of direct-acting antivirals...
  10. pmc Characterization of serum proteins associated with IL28B genotype among patients with chronic hepatitis C
    Derek D Cyr
    Institute for Genome Sciences and Policy, Duke University Medical Center, Durham, North Carolina, United States of America
    PLoS ONE 6:e21854. 2011
    ..To gain further insight into IL28B function we assessed the association of rs12979860 with expression of protein quantitative traits (pQTL analysis) generated using open-platform proteomics in serum from patients...
  11. doi request reprint Insulin resistance is independently associated with significant hepatic fibrosis in Asian chronic hepatitis C genotype 2 or 3 patients
    Keyur Patel
    Duke Clinical Research Institute, Duke University, Durham, North Carolina, USA
    J Gastroenterol Hepatol 26:1182-8. 2011
    ..We retrospectively investigated the relationship between host metabolic variables, including IR and hepatic steatosis, to hepatic fibrosis in Asian-region CHC genotype 2/3 patients...
  12. doi request reprint Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR
    Alexander J Thompson
    Duke Clinical Research Institute, Durham, NC, USA
    Hepatology 53:389-95. 2011
    ..Conclusion: Two ITPA variants were strongly associated with protection against treatment-related anemia in patients with genotype 2/3 HCV, but they did not decrease the need for RBV dose reduction or increase the rate of SVR...
  13. doi request reprint Noninvasive tools to assess liver disease
    Paul J Clark
    GI Hepatology Division, Duke Clinical Research Institute and Duke University Medical Center, Durham, North Carolina 27715, USA
    Curr Opin Gastroenterol 27:210-6. 2011
    ..To improve understanding of recent developments in the noninvasive assessment of fibrosis and their potential clinical application to a range of chronic liver diseases...